SCHEMBL6283003

SCHEMBL6283003

CC(C)(C)OC(=O)CC1CNC(=O)N1Cc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLA2G10 O15496 1/20 0.42
PLA2G5 P39877 1/20 0.42
KMT2A Q03164 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
USP2 O75604 1/20 0.38
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
HDAC2 Q92769 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
ATM Q13315 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
BRD4 O60885 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6283964 0.82 ITGB1 (0.44) KMT2AMEN1ALDH1A1HDAC2HDAC8
SCHEMBL6282333 0.80 PLA2G10 (0.40) PLA2G10PLA2G5KMT2AALDH1A1
SCHEMBL6283590 0.76 PLA2G10 (0.38) PLA2G10PLA2G5ALDH1A1SMN1; SMN2
SCHEMBL13986107 0.74 EHMT2 (0.46) KMT2AMEN1HDAC2HDAC8HDAC6
SCHEMBL9347752 0.73 KMT2A (0.48) PLA2G10PLA2G5KMT2AL3MBTL1MEN1
SCHEMBL11360254 0.71 TSHR (0.49) KMT2AL3MBTL1MEN1ALDH1A1TDP1
SCHEMBL10994281 0.71 TSHR (0.49) KMT2AL3MBTL1MEN1ALDH1A1TDP1
SCHEMBL4293137 0.70 EHMT2 (0.45) KMT2AMEN1HDAC2HDAC8HDAC6
SCHEMBL6010427 0.70 CYP3A4 (0.38) KMT2AL3MBTL1ALDH1A1TDP1HDAC2
SCHEMBL5806806 0.69 POLB (0.42) KMT2AALDH1A1TDP1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6852744-B2 Pyrrolidine derivatives and their use as chymase inhibitor DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2005-02-08 US disclosed
US-20040102384-A1 Pyrrolidine derivatives and their use as chymase inhibitor DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-05-27 US disclosed
EP-1313730-A1 PYRROLIDINE DERIVATIVES AND THEIR USE AS CHYMASE INHIBITOR Dainippon Pharmaceutical Co., Ltd. (JP) 2003-05-28 EP disclosed
WO-2002018378-A1 PYRROLIDINE DERIVATIVES AND THEIR USE AS CHYMASE INHIBITOR DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102384-A1 Pyrrolidine derivatives and their use as chymase inhibitor CMA1, CTRL, TPSD1 PLA2G10 4224/4885PLA2G5 3701/4885KMT2A 3249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.